How wealthy self-made beauty is reduced? -Theranos startups-IT information
Last year, Theranos blood testing company co-founder and CEO Elizabeth Holmes net worth up to $ 4.5 billion, success on the Forbes list of the richest self-made women billionaires across the United States topped the list. Today, Forbes put her net worth was cut to zero. At present, Theronos has yet to comment on the matter.
We are forecasting statistics based on all of Holmes's wealth Theranos that she owns 50% shares of the company. Theranos Holmes is a blood testing company founded in 2003, aims to revolutionise blood testing market. Theranos stock is not currently in the public stock market transactions, private investors bought in 2014, Theranos shares valued it at $ 9 billion.
Since then, Theranos was being repeatedly questioned said the blood test results are inaccurate, then begin investigations by the Federal Agency. In order to avoid a deterioration of the situation, Theranos blood testing equipment has been "Edison" in the last two years revoked the testing results and sent tens of thousands of corrections to the doctors and patients of medical examination report. Subsequently, reports Theronos annual revenue of less than $ 100 million, all of these factors eventually led to Forbes cut Theranos valuations.
Forbes and dozens of venture capitalists, analysts and industry experts have spoken, and finally come to a new conclusion, namely Theranos is valued at just US $ 800 million, not $ 9 billion. VC Experts say venture capital research institutions, Theranos primarily valued based on what the company has several patents before and have access to 724 million dollars in financing. According to insiders familiar with the Theranos finances, Theronos the current turnover of 800 million dollar valuation is currently several times.
Theranos now only $ 800 million valuation, 50% shares in the company held by Holmes himself basically worthless. Theranos investor owns preferred shares in the company, while Holmes has is common stock, this means that Holmes only Singapore investors can exchange their preferred shares into common stock. According to VC Experts said Theranos is a special type of preferred stock owned by the investors, called participating preferred stock. This means Theranos liquidation in the case, Holmes of investors and ordinary shares over the right of liquidation. Is not known whether Theranos liquidation plans. If it really happens, with participating preferred stock investors to get their money back before the Holmes, but Holmes himself might not get anything.
In the future, Holmes may be from existing investor to the company valuation of more than $ 800 million to thaw a sum of money, but no one knows can get. Here is Forbes cut Theranos valuations of the three major reasons:
1. Theranos there are too many things we don't know. In addition to the valuation of US $ 9 billion, a Theranos the seems to us to be secret. Theranos said it was intended to completely replace the traditional blood test. Traditional blood tests is that doctors need to use long needles and several blood test tube bottles of blood collected, samples are then sent to a laboratory for analysis. Theranos claimed his blood test requires only one to two drops of blood collected from patients with finger can perform a variety of tests. But so far, Theranos does not provide its own evidence of feasibility data.
2. failed to honour its promise. Holmes had previously promised to publish the data, but as of April this year, the company still has not submitted a report. Holmes most began to outside show has United States food and drug authority approved himself of a items simple for herpes virus 1 type of detection technology, and no approved other virus of detection, but Theranos is to this to misleading mass, claimed himself of laboratory detection technology was FDA approved, and no stressed was batch of just is detection herpes virus of technology, other project of detection yet get FDA of approved. At present, Theranos has set aside tens of thousands of test results.
3. Theranos target market may not exist at all. Theranos, some industry experts estimate can and United States experimental holding (market value of US $ 13 billion) and Quest Diagnostics company (market value of us $ 1.1 billion) is extremely doubtful. Theranos per test fee is very low, hence the need to substantially improve the profit of each test, while allowing users to use their own blood testing technology as much as possible.
Holmes will be in August this year in the United States Association for clinical chemistry (AACC) meeting Theranos related data. At that time might know exactly what Theranos hand technology to support their own technology that can be used. However, considering the present plight of Theranos, Holmes not only fell off the Forbes name United States the wealthiest self-made female billionaires list, and am all fell out of the Forbes rich list.
白手起家的美女富豪是如何沦落的？ - Theranos,初创公司 - IT资讯
去年，血液检测公司Theranos的联合创始人兼CEO Elizabeth Holmes净资产高达45亿美元，成功登上福布斯全美最富有的白手起家的女富豪榜单的榜首。今天，福布斯却将她的个人净资产下调为零。目前，Theronos尚未对此事做任何评论。
我们对Holmes财富的预测统计全部基于她所拥有的Theranos公司的50%的股份。Theranos是Holmes于2003年创办的一家血液检测公司，旨在彻底变革血液检测市场。Theranos的股票目前没有在公开的股票市场交易，私人投资者在2014年购买Theranos的股票时对它的估值为90亿美元。
自那时开始，Theranos被开始被屡次质疑说它的血液检测结果是不准确的，于是开始被联邦机构调查。为了避免事态恶化，Theranos已将血液检测仪器“爱迪生”在过去两年的检测结果全部作废，并向医生和病人发出了数万份更正医疗检验报告。后来又有消息称Theronos的年营收额不足1亿美元，所有这些因素最终导致福布斯下调Theranos的估值。
福布斯和数十位风险资本家、分析师和行业专家进行了沟通，最后得出了一个新的结论，即Theranos目前的估值仅为8亿美元，而不是90亿美元。风险资本研究机构VC Experts表示，Theranos的估值主要基于公司所拥有的一些专利和之前已经获得的7.24亿美元的融资。据熟悉Theranos财务状况的内部人士透露，Theronos目前8亿美元的估值是公司目前营业额的数倍。
基于Theranos目前仅有的8亿美元的估值，Holmes自己所持有的公司50%的股份基本毫无价值。Theranos的投资者拥有公司的优先股，而Holmes拥有的则是普通股，这意味着，Holmes只有在投资者兑换了优先股后才能兑换自己的普通股。据VC Experts消息称，Theranos的投资者拥有的是一种特别的优先股，称为参与优先股。这意味着Theranos在被清算的情况下，投资者和拥有普通股的Holmes相比拥有优先清算权。目前还不知道Theranos是否有清算的打算。如果真的发生的话，拥有参与优先股的投资者能够在Holmes之前拿回自己的钱，而Holmes自己可能什么也拿不到。
在未来，Holmes可能会从公司现有的投资方那里以高于8亿美元估值的方式再去融一笔钱，但能否融到谁也不知道。下面是福布斯下调Theranos估值的三大原因：
1. Theranos有太多我们不知道的东西。除了90亿美元的估值外，Theranos的其它一切对我们来说好像都是秘密。Theranos说它的目的是彻底取代传统的血液检测方式。传统的血液检测方法是，医生需要使用长针头和几个装血液的试管瓶完成血液采集，然后将样本送往实验室进行分析。而Theranos声称自己的血液检测方法仅需要从患者手指采集一到两滴血液就可以完成各种检测。但到目前为止，Theranos都没有提供自己的方法可行性的数据证据。
2.未能履行承诺。Holmes之前曾承诺过会公布一些数据，但截至今年4月，公司依然未提交一份报告。Holmes最开始向外界展示了美国食品和药物管理局批准自己的一项单纯针对疱疹病毒1型的检测技术，而没有批准其它病毒的检测，但Theranos却以此来误导大众，声称自己的实验室检测技术获FDA批准，而没有强调获批的仅仅是检测疱疹病毒的技术，其它项目的检测尚未得到FDA的批准。目前，Theranos已经作废了上万份检测结果。
3. Theranos的目标市场可能根本就不存在。一些行业专家对Theranos的估值是否能与美国实验控股（市值130亿美元）和奎斯特诊断公司（市值11亿美元）是表示极度怀疑的。Theranos每次检测的收费很低，因此需要大幅提高每次检测的利润，同时让尽可能多的用户使用自己的血液检测技术。
Holmes将会在今年8月份在美国临床化学协会（AACC）年会上公布Theranos的相关数据。那时可能就会知道Theranos手里到底有哪些技术可以支撑自己的技术是可以被使用的。不过考虑到目前Theranos的艰难处境，Holmes的名字不仅跌出了福布斯美国最富有白手起家女富豪的榜单，还跌出了福布斯所有富豪类的榜单。